Recent Updates
Recently added Catalysts
ATYR Negative Sentiment Score: 20/100

ATYR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that aTyr Pharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Key Takeaway: Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against aTyr Pharma, Inc., representing investors who incurred significant losses. The lawsuit alleges that the company made false and misleading statements regarding the drug Efzofitimod and its efficacy, particularly in relation to tapering steroid usage. Investors are encouraged to join the lawsuit if they purchased aTyr securities during the specified class period from January 16 to September 12, 2025. The firm operates on a contingency fee basis, meaning that costs are covered only upon a successful recovery.

Market Sentiment Analysis

CONCERNS & RISKS

  • A class action lawsuit has been filed against aTyr Pharma, alleging violations of federal securities laws.
  • The complaint claims that aTyr misled investors regarding the efficacy of Efzofitimod, providing false statements.
  • The company allegedly concealed adverse facts about the drug's ability to help patients taper steroid use.
  • Investors purchased securities at artificially inflated prices due to these misrepresentations.

Full Press Release Details

NEW YORK, Nov. 27, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against aTyr Pharma, Inc. (“aTyr” or “the Company”) (NASDAQ: ATYR) and certain of its officers.
This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired aTyr securities between January 16, 2025 and September 12, 2025, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/ATYR.
The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose that: (1) Defendants provided overwhelmingly positive statements to investors regarding the efficacy of Efzofitimod; (2) At the same time, Defendants disseminated false and misleading statements and/or concealed material adverse facts concerning the drug’s actual capability—particularly its ability to enable patients to completely taper their steroid usage; and (3) As a result of these omissions and misrepresentations, Plaintiff and other shareholders purchased aTyr’s securities at artificially inflated prices.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: bgandg.com/ATYR. or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660. If you suffered a loss in aTyr you have until December 8, 2025, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.
There is No Cost to You
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Follow us for updates on LinkedIn, X, Facebook, or Instagram.
Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | info@bgandg.com

Tags

Frequently Asked Questions

What is the class action lawsuit against aTyr Pharma about?

It alleges misleading statements and omissions regarding the drug Efzofitimod.

Who can join the aTyr class action lawsuit?

Investors who acquired aTyr securities between January 16 and September 12, 2025.

What is the deadline to become a lead plaintiff in the aTyr case?

You must request lead plaintiff status by December 8, 2025.

Is there any cost to participate in the lawsuit?

No, participation is on a contingency fee basis, with costs if successful.

Where can I find more information about the lawsuit?

Visit bgandg.com/ATYR for details and to review the Complaint.

Last updated: Nov 27, 2025